VolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a research report issued to clients and investors on Thursday. The brokerage set a “sell” rating on the stock.

Separately, Benchmark reiterated a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd.

VolitionRx Stock Up 1.6 %

Shares of VolitionRx stock opened at $0.70 on Thursday. VolitionRx has a 52-week low of $0.43 and a 52-week high of $1.23. The company has a 50 day moving average of $0.69 and a 200 day moving average of $0.68. The company has a market capitalization of $64.57 million, a P/E ratio of -1.94 and a beta of 1.10.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in VolitionRx stock. Geode Capital Management LLC lifted its stake in shares of VolitionRx Limited (NYSE:VNRX) by 15.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 730,448 shares of the company’s stock after buying an additional 95,900 shares during the quarter. Geode Capital Management LLC owned about 0.79% of VolitionRx worth $439,000 at the end of the most recent reporting period. 8.09% of the stock is owned by institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.